♥
ISIN : INE351A01035
NSE : UNICHEMLAB
BSE : 506690
Face Value : 2
Industry : Pharmaceuticals & Drugs
EPS : -10.01
EPS (TTM) : -8.61
Price to Earning (P/E) : -69.62
Book Value : 335.11
Price to Bookvalue (P/B) : 2.08
Dividend Yield : 1 %
Return on Equity (ROE) : -2.95 %
Return on Capital Employed (ROCE) : -1.47 %
Unichem Laboratories Limited
ISIN : INE351A01035
NSE : UNICHEMLAB
BSE : 506690
Face Value : 2
Industry : Pharmaceuticals & Drugs
EPS : -10.01
EPS (TTM) : -8.61
Price to Earning (P/E) : -69.62
Book Value : 335.11
Price to Bookvalue (P/B) : 2.08
Dividend Yield : 1 %
Return on Equity (ROE) : -2.95 %
Return on Capital Employed (ROCE) : -1.47 %
Unichem Laboratories share price(02-Apr-2026) | |
|---|---|
| Open / Close | 0 - 0 NAN % |
| Low / High | 0 - 0 NAN % |
| Trade Volume | 0 |
| 52 Week Low / High | 0 - 0 NAN % |
| Open / Close | 292.55 - 298.45 2 % |
| Low / High | 291.7 - 300.65 3.1 % |
| Trade Volume | 733 |
| 52 Week Low / High | 280 - 668 138.6 % |
-
YOU MAY ALSO LIKE
- How much money do you need to retire
Know how much money do you need to retire, before how much to invest ? - CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator - Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE - Stock market course tutorial
Stock Market Investment Course explained in simple words. - High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE - Share Market basics for beginners
Share Market jargons in simple terms
CONSOLIDATED QUARTERLY RESULT FOR UNICHEM LABORATORIES LIMITED
| Date End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 3699.54 | 3096.08 | 3288.19 | 3024.95 | 4020.99 | 4231.87 | 4156.29 | 4343.79 | 4317 | 4464.33 |
| Total Income | 3843.44 | 3174.56 | 3380.25 | 3188.46 | 4072.1 | 4318.17 | 4211.64 | 4456.55 | 4378.53 | 4502.94 |
| Total Expenditure | 3015.19 | 3105.73 | 3471.31 | 3452.58 | 3856.15 | 3951.68 | 4068.66 | 3962.63 | 4063.49 | 4029.36 |
| Other Income | 143.9 | 78.47 | 92.06 | 163.51 | 51.11 | 86.31 | 55.36 | 112.77 | 61.53 | 38.61 |
| Operating Profit | 828.25 | 68.83 | -91.06 | -264.12 | 215.95 | 366.49 | 142.98 | 493.92 | 315.04 | 473.58 |
| Interest | 15.86 | 30.11 | 46.91 | 40.86 | 55.24 | 57.61 | 67.26 | 55.8 | 45.94 | 40.34 |
| Exceptional Items | -50.22 | -335.44 | 680.15 | -1256.23 | ||||||
| PBDT | 812.39 | 38.72 | -188.19 | -304.98 | -174.73 | 308.88 | 75.72 | 1118.27 | -987.13 | 433.24 |
| Depreciation | 233.05 | 245.45 | 284.34 | 307.82 | 296.83 | 287.71 | 294.55 | 278.58 | 271.57 | 283.26 |
| Profit Before Tax | 579.34 | -206.73 | -472.53 | -612.8 | -471.56 | 21.17 | -218.83 | 839.69 | -1258.7 | 149.98 |
| Tax | -135.37 | 26.94 | 234.13 | 26.48 | -28.91 | 27.85 | 26.06 | -0.23 | 34.4 | 57.43 |
| Profit After Tax | 714.71 | -233.67 | -706.66 | -639.28 | -442.65 | -6.68 | -244.89 | 839.92 | -1293.1 | 92.55 |
| Net Profit | 714.71 | -233.67 | -706.66 | -639.28 | -442.65 | -6.68 | -244.89 | 839.92 | -1293.1 | 92.55 |
| Equity Capital | 140.81 | 140.81 | 140.81 | 140.81 | 140.81 | 140.81 | 140.81 | 140.81 | 140.81 | 140.81 |
| Face Value (IN RS) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Calculated EPS | 10.15 | -3.32 | -10.04 | -9.08 | -6.29 | -0.09 | -3.48 | 11.93 | -18.37 | 1.31 |
| Diluted Eps After Extraordinary Items | 10.14 | -3.32 | -10.04 | -9.08 | -6.28 | -0.09 | -3.48 | 11.92 | -18.36 | 1.31 |
| Diluted Eps Before Extraordinary Items | 10.14 | -3.32 | -10.04 | -9.08 | -6.28 | -0.09 | -3.48 | 11.92 | -18.36 | 1.31 |
STANDALONE QUARTERLY RESULT FOR UNICHEM LABORATORIES LIMITED
| Date End | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 2768.65 | 2447.81 | 2656.38 | 2519.48 | 3100.64 | 3466.67 | 3338.3 | 3624.27 | 3992.43 | 3897.48 |
| Total Income | 2859.43 | 2566.27 | 2764.19 | 2673.81 | 3138.53 | 3524.93 | 3414.11 | 3723.7 | 4062.8 | 3985.22 |
| Total Expenditure | 2643.73 | 2556.68 | 2967.7 | 2941.11 | 3187.96 | 3383.58 | 3411.37 | 3431.05 | 3686.49 | 3495.49 |
| Other Income | 90.78 | 118.45 | 107.8 | 154.33 | 37.88 | 58.26 | 75.81 | 99.42 | 70.37 | 87.74 |
| Operating Profit | 215.7 | 9.59 | -203.51 | -267.3 | -49.43 | 141.35 | 2.74 | 292.65 | 376.31 | 489.73 |
| Interest | 5.77 | 16.67 | 30.21 | 17.61 | 29.32 | 24.75 | 38.25 | 23.62 | 17.58 | 13.82 |
| Exceptional Items | -50.22 | -1076.42 | 680.15 | -1256.23 | ||||||
| PBDT | 209.93 | -7.08 | -283.94 | -284.91 | -1155.17 | 116.6 | -35.51 | 949.18 | -897.5 | 475.91 |
| Depreciation | 212.68 | 225.7 | 264.57 | 286.35 | 283.18 | 273.63 | 272.59 | 256.17 | 252.19 | 261.07 |
| Profit Before Tax | -2.75 | -232.78 | -548.51 | -571.26 | -1438.35 | -157.03 | -308.1 | 693.01 | -1149.69 | 214.84 |
| Tax | -176.07 | 206.12 | ||||||||
| Profit After Tax | 173.32 | -232.78 | -754.63 | -571.26 | -1438.35 | -157.03 | -308.1 | 693.01 | -1149.69 | 214.84 |
| Net Profit | 173.32 | -232.78 | -754.63 | -571.26 | -1438.35 | -157.03 | -308.1 | 693.01 | -1149.69 | 214.84 |
| Equity Capital | 140.81 | 140.81 | 140.81 | 140.81 | 140.81 | 140.81 | 140.81 | 140.81 | 140.81 | 140.81 |
| Face Value (IN RS) | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Calculated EPS | 2.46 | -3.31 | -10.72 | -8.11 | -20.43 | -2.23 | -4.38 | 9.84 | -16.33 | 3.05 |
| Diluted Eps After Extraordinary Items | 2.46 | -3.31 | -10.72 | -8.11 | -20.43 | -2.23 | -4.38 | 9.85 | -16.33 | 3.04 |
| Diluted Eps Before Extraordinary Items | 2.46 | -3.31 | -10.72 | -8.11 | -20.43 | -2.23 | -4.38 | 9.85 | -16.33 | 3.04 |
CONSOLIDATED ANNUAL RESULT FOR UNICHEM LABORATORIES LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 12698.3 | 13430.2 | 17048.9 |
| Total Income | 13173.4 | 13815.4 | 17364.9 |
| Total Expenditure | 11970.4 | 13885.8 | 16046.5 |
| Other Income | 475.09 | 385.15 | 315.95 |
| Operating Profit | 1203.01 | -70.4 | 1318.44 |
| Interest | 61.05 | 173.12 | 226.61 |
| Exceptional Items | -385.66 | -576.08 | |
| PBDT | 1141.96 | -629.18 | 515.75 |
| Depreciation | 911.66 | 1134.44 | 1132.4 |
| Profit Before Tax | 230.3 | -1763.62 | -616.65 |
| Tax | -110.93 | 258.65 | 88.08 |
| Profit After Tax | 341.23 | -2022.27 | -704.73 |
| Net Profit | 341.23 | -2022.27 | -704.73 |
| Equity Capital | 140.81 | 140.81 | 140.81 |
| Face Value (IN RS) | 2 | 2 | 2 |
| Reserves | 26043.3 | 24212.2 | 23483.4 |
| Calculated EPS | 4.7 | -28.72 | -10.01 |
| Diluted Eps After Extraordinary Items | 4.68 | -28.72 | -10.01 |
| Diluted Eps Before Extraordinary Items | 4.68 | -28.72 | -10.01 |
STANDALONE ANNUAL RESULT FOR UNICHEM LABORATORIES LIMITED
| Date End | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|
| No of months | 12 months | 12 months | 12 months |
| Net Sales | 9429.27 | 10724.3 | 14421.7 |
| Total Income | 9849.94 | 11142.8 | 14725.5 |
| Total Expenditure | 9864.81 | 11653.5 | 13912.5 |
| Other Income | 420.68 | 418.48 | 303.86 |
| Operating Profit | -14.87 | -510.65 | 813.05 |
| Interest | 20.74 | 93.8 | 104.2 |
| Exceptional Items | -1126.64 | -576.08 | |
| PBDT | -35.61 | -1731.09 | 132.77 |
| Depreciation | 831.88 | 1059.79 | 1054.58 |
| Profit Before Tax | -867.49 | -2790.88 | -921.81 |
| Tax | -313.18 | 206.12 | |
| Profit After Tax | -554.31 | -2997 | -921.81 |
| Net Profit | -554.31 | -2997 | -921.81 |
| Equity Capital | 140.81 | 140.81 | 140.81 |
| Face Value (IN RS) | 2 | 2 | 2 |
| Reserves | 26579.6 | 23701.9 | 22805.4 |
| Calculated EPS | -7.87 | -42.57 | -13.09 |
| Diluted Eps After Extraordinary Items | -7.87 | -42.57 | -13.09 |
| Diluted Eps Before Extraordinary Items | -7.87 | -42.57 | -13.09 |
CONSOLIDATED PROFIT / LOSS FOR UNICHEM LABORATORIES LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 1235.14 Cr | 1269.83 Cr | 1343.02 Cr | 1704.89 Cr |
| Sales | 1189.92 Cr | 1247.98 Cr | 1302.42 Cr | 1657.42 Cr |
| Net Sales | 1235.14 Cr | 1269.83 Cr | 1343.02 Cr | 1704.89 Cr |
| Increase/Decrease in Stock | -88.14 Cr | -41.53 Cr | 17.2 Cr | -79.09 Cr |
| Raw Material Consumed | 390.28 Cr | 398.44 Cr | 465.25 Cr | 644.72 Cr |
| Opening Raw Materials | 166.81 Cr | 213 Cr | 233.56 Cr | 253.57 Cr |
| Purchases Raw Materials | 435.99 Cr | 417.66 Cr | 483.73 Cr | 651.76 Cr |
| Closing Raw Materials | 213.06 Cr | 233.56 Cr | 253.57 Cr | 261.53 Cr |
| Other Direct Purchases / Brought in cost | 53.52 Lk | 1.35 Cr | 1.53 Cr | 91.09 Lk |
| Power & Fuel Cost | 68.89 Cr | 78.05 Cr | 102.84 Cr | 107.14 Cr |
| Electricity & Power | 68.89 Cr | 78.05 Cr | 102.84 Cr | 107.14 Cr |
| Employee Cost | 306.97 Cr | 330.49 Cr | 356.41 Cr | 393.06 Cr |
| Salaries, Wages & Bonus | 281.04 Cr | 302.75 Cr | 327.83 Cr | 356.07 Cr |
| Contributions to EPF & Pension Funds | 14.75 Cr | 17.11 Cr | 19.46 Cr | 25.51 Cr |
| Workmen and Staff Welfare Expenses | 8.35 Cr | 7.78 Cr | 8.08 Cr | 8.39 Cr |
| Other Manufacturing Expenses | 215.73 Cr | 193.22 Cr | 194.6 Cr | 227.8 Cr |
| Repairs and Maintenance | 46.64 Cr | 52.72 Cr | 55.46 Cr | 58.13 Cr |
| Packing Material Consumed | 77.24 Cr | 58.92 Cr | 68.47 Cr | 99 Cr |
| General and Administration Expenses | 123.98 Cr | 109.6 Cr | 119.02 Cr | 133.02 Cr |
| Rent , Rates & Taxes | 5.86 Cr | 5.52 Cr | 7.39 Cr | 5.34 Cr |
| Insurance | 9.94 Cr | 10.75 Cr | 11.51 Cr | 11.38 Cr |
| Professional and legal fees | 50.18 Cr | 38.41 Cr | 42.68 Cr | 55.53 Cr |
| Traveling and conveyance | 98.22 Lk | 3.12 Cr | 5.39 Cr | 4.96 Cr |
| Selling and Distribution Expenses | 122.52 Cr | 120.68 Cr | 129.56 Cr | 178 Cr |
| Advertisement & Sales Promotion | 2.68 Cr | 14.41 Cr | 11.75 Cr | 15.77 Cr |
| Sales Commissions & Incentives | 2.06 Cr | 2.14 Cr | 1.94 Cr | 1.31 Cr |
| Freight and Forwarding | 117.78 Cr | 104.12 Cr | 115.87 Cr | 160.92 Cr |
| Miscellaneous Expenses | 3.81 Cr | 8.11 Cr | 3.7 Cr | 0 |
| Loss on disposal of fixed assets(net) | 52.26 Lk | 23.43 Lk | 0 | 0 |
| Total Expenditure | 1144.03 Cr | 1197.04 Cr | 1388.58 Cr | 1604.65 Cr |
| Other Income | 50.19 Cr | 47.51 Cr | 38.52 Cr | 31.6 Cr |
| Interest Received | 22.94 Cr | 6.48 Cr | 51.62 Lk | 67.26 Lk |
| Dividend Received | 36,000 | 10.01 Cr | 59,000 | 43,000 |
| Profit on sale of Fixed Assets | 0 | 0 | 1.28 Cr | 1.63 Cr |
| Profits on sale of Investments | 11.64 Cr | 0 | 0 | 0 |
| Foreign Exchange Gains | 10.54 Cr | 27.38 Cr | 27.32 Cr | 22.4 Cr |
| Operating Profit | 141.3 Cr | 120.3 Cr | -7.04 Cr | 131.84 Cr |
| Interest | 5.12 Cr | 6.11 Cr | 17.31 Cr | 22.66 Cr |
| Bank Charges etc | 65.02 Lk | 1.08 Cr | 1.06 Cr | 50.65 Lk |
| PBDT | 136.18 Cr | 114.2 Cr | -24.35 Cr | 109.18 Cr |
| Depreciation | 84.36 Cr | 91.17 Cr | 113.44 Cr | 113.24 Cr |
| Profit Before Taxation & Exceptional Items | 51.82 Cr | 23.03 Cr | -137.8 Cr | -4.06 Cr |
| Exceptional Income / Expenses | 0 | 0 | -38.57 Cr | -57.61 Cr |
| Profit Before Tax | 51.82 Cr | 23.03 Cr | -176.36 Cr | -61.67 Cr |
| Provision for Tax | 17.15 Cr | -11.09 Cr | 25.86 Cr | 8.81 Cr |
| Current Income Tax | 16.68 Cr | 10.51 Cr | 11.06 Cr | 7.94 Cr |
| Deferred Tax | -14.82 Lk | -21.84 Cr | 15.35 Cr | 86.33 Lk |
| Profit After Tax | 34.67 Cr | 34.12 Cr | -202.23 Cr | -70.47 Cr |
| Share of Associate | -34.25 Lk | -1.06 Cr | 0 | 0 |
| Consolidated Net Profit | 34.32 Cr | 33.06 Cr | -202.23 Cr | -70.47 Cr |
| Profit Balance B/F | 2495.02 Cr | 2501.18 Cr | 2506.08 Cr | 2397.51 Cr |
| Appropriations | 2529.34 Cr | 2534.24 Cr | 2303.85 Cr | 2327.03 Cr |
| Other Appropriation | 28.16 Cr | 28.16 Cr | -93.65 Cr | -12.05 Cr |
| Equity Dividend % | 200 | 200 | 0 | 0 |
| Earnings Per Share | 4.88 | 4.7 | -28.72 | -10.01 |
| Adjusted EPS | 4.88 | 4.7 | -28.72 | -10.01 |
STANDALONE PROFIT / LOSS FOR UNICHEM LABORATORIES LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Gross Sales | 1123.97 Cr | 942.93 Cr | 1072.43 Cr | 1442.17 Cr |
| Sales | 1078.52 Cr | 919.18 Cr | 1030.51 Cr | 1392.62 Cr |
| Net Sales | 1123.97 Cr | 942.93 Cr | 1072.43 Cr | 1442.17 Cr |
| Increase/Decrease in Stock | -16.73 Cr | -52.79 Cr | 22.01 Cr | -26.36 Cr |
| Raw Material Consumed | 376.06 Cr | 377.35 Cr | 433.39 Cr | 618.83 Cr |
| Opening Raw Materials | 161.42 Cr | 207.77 Cr | 229.77 Cr | 249.08 Cr |
| Purchases Raw Materials | 421.88 Cr | 398 Cr | 451.16 Cr | 619.5 Cr |
| Closing Raw Materials | 207.77 Cr | 229.77 Cr | 249.08 Cr | 250.66 Cr |
| Other Direct Purchases / Brought in cost | 53.52 Lk | 1.35 Cr | 1.53 Cr | 91.09 Lk |
| Power & Fuel Cost | 67.95 Cr | 77.12 Cr | 101.41 Cr | 105.64 Cr |
| Electricity & Power | 67.95 Cr | 77.12 Cr | 101.41 Cr | 105.64 Cr |
| Employee Cost | 234.04 Cr | 250.79 Cr | 270.86 Cr | 283.14 Cr |
| Salaries, Wages & Bonus | 208.96 Cr | 223.74 Cr | 242.38 Cr | 254.85 Cr |
| Contributions to EPF & Pension Funds | 14.75 Cr | 17.11 Cr | 19.46 Cr | 20.02 Cr |
| Workmen and Staff Welfare Expenses | 8.08 Cr | 7.7 Cr | 7.98 Cr | 8.27 Cr |
| Other Manufacturing Expenses | 138.1 Cr | 189.1 Cr | 189.07 Cr | 222.94 Cr |
| Repairs and Maintenance | 43.64 Cr | 49.89 Cr | 52.31 Cr | 54.33 Cr |
| Packing Material Consumed | 73.61 Cr | 58.92 Cr | 68.47 Cr | 99 Cr |
| General and Administration Expenses | 164.37 Cr | 82.51 Cr | 88.02 Cr | 93.26 Cr |
| Rent , Rates & Taxes | 4.46 Cr | 3.91 Cr | 6.17 Cr | 3.77 Cr |
| Insurance | 5.78 Cr | 6.49 Cr | 7.06 Cr | 6.71 Cr |
| Professional and legal fees | 14.49 Cr | 27.12 Cr | 27.82 Cr | 37.18 Cr |
| Traveling and conveyance | 64.93 Lk | 1.94 Cr | 3.45 Cr | 1.94 Cr |
| Selling and Distribution Expenses | 61.44 Cr | 53.45 Cr | 56.88 Cr | 93.79 Cr |
| Advertisement & Sales Promotion | 9.76 Lk | 28.12 Lk | 48.07 Lk | 54.67 Lk |
| Sales Commissions & Incentives | 1.76 Cr | 2.46 Cr | 2.26 Cr | 2.86 Cr |
| Freight and Forwarding | 59.58 Cr | 50.71 Cr | 54.13 Cr | 90.38 Cr |
| Miscellaneous Expenses | 3.28 Cr | 8.95 Cr | 3.7 Cr | 0 |
| Loss on disposal of fixed assets(net) | 0 | 25.34 Lk | 0 | 0 |
| Total Expenditure | 1028.51 Cr | 986.48 Cr | 1165.35 Cr | 1391.25 Cr |
| Other Income | 47.37 Cr | 42.07 Cr | 41.85 Cr | 30.39 Cr |
| Interest Received | 22.88 Cr | 6.27 Cr | 23.99 Lk | 43.87 Lk |
| Dividend Received | 36,000 | 10.01 Cr | 59,000 | 43,000 |
| Profit on sale of Fixed Assets | 2.57 Lk | 0 | 1.28 Cr | 1.67 Cr |
| Profits on sale of Investments | 11.64 Cr | 0 | 0 | 0 |
| Foreign Exchange Gains | 11.71 Cr | 21.79 Cr | 30.72 Cr | 21.23 Cr |
| Operating Profit | 142.84 Cr | -1.49 Cr | -51.07 Cr | 81.31 Cr |
| Interest | 1.3 Cr | 2.07 Cr | 9.38 Cr | 10.42 Cr |
| Bank Charges etc | 65.02 Lk | 1.08 Cr | 1.06 Cr | 50.65 Lk |
| PBDT | 141.54 Cr | -3.56 Cr | -60.45 Cr | 70.89 Cr |
| Depreciation | 75.89 Cr | 83.19 Cr | 105.98 Cr | 105.46 Cr |
| Profit Before Taxation & Exceptional Items | 65.65 Cr | -86.75 Cr | -166.42 Cr | -34.57 Cr |
| Exceptional Income / Expenses | 0 | 0 | -112.66 Cr | -57.61 Cr |
| Profit Before Tax | 65.65 Cr | -86.75 Cr | -279.09 Cr | -92.18 Cr |
| Provision for Tax | 11.56 Cr | -31.32 Cr | 20.61 Cr | 0 |
| Deferred Tax | 10.94 Cr | -31.56 Cr | 20.61 Cr | 0 |
| Profit After Tax | 54.08 Cr | -55.43 Cr | -299.7 Cr | -92.18 Cr |
| Consolidated Net Profit | 54.08 Cr | -55.43 Cr | -299.7 Cr | -92.18 Cr |
| Profit Balance B/F | 2623.04 Cr | 2648.96 Cr | 2565.36 Cr | 2359.31 Cr |
| Appropriations | 2677.12 Cr | 2593.53 Cr | 2265.66 Cr | 2267.13 Cr |
| Other Appropriation | 28.16 Cr | 28.16 Cr | -93.65 Cr | -12.05 Cr |
| Equity Dividend % | 200 | 200 | 0 | 0 |
| Earnings Per Share | 7.68 | -7.87 | -42.57 | -13.09 |
| Adjusted EPS | 7.68 | -7.87 | -42.57 | -13.09 |
CONSOLIDATED CASH FLOW FOR UNICHEM LABORATORIES LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 51.48 Cr | 21.97 Cr | -176.36 Cr | -61.67 Cr |
| Adjustment | 65.65 Cr | 80.46 Cr | 132.84 Cr | 187.39 Cr |
| Changes In working Capital | -69.67 Cr | -354.43 Cr | -29.36 Cr | -102.65 Cr |
| Cash Flow after changes in Working Capital | 47.46 Cr | -252 Cr | -72.88 Cr | 23.07 Cr |
| Cash Flow from Operating Activities | 33.1 Cr | -259.61 Cr | -85.09 Cr | 16.69 Cr |
| Cash Flow from Investing Activities | -73.56 Cr | 100.12 Cr | 202.81 Cr | 50.4 Cr |
| Cash Flow from Financing Activitie | -121.19 Cr | 191.23 Cr | -81.3 Cr | -106.31 Cr |
| Net Cash Inflow / Outflow | -161.65 Cr | 31.74 Cr | 36.42 Cr | -39.21 Cr |
| Opening Cash & Cash Equivalents | 231.52 Cr | 77.46 Cr | 109.2 Cr | 183.75 Cr |
| Cash & Cash Equivalent on Amalgamation / Take over / Merger | 7.59 Cr | 0 | 38.13 Cr | 6.37 Cr |
| Closing Cash & Cash Equivalent | 77.46 Cr | 109.2 Cr | 183.75 Cr | 150.91 Cr |
STANDALONE CASH FLOW FOR UNICHEM LABORATORIES LIMITED
| Year End | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| No of Months | 12 months | 12 months | 12 months | 12 months |
| Profit Before Tax | 65.65 Cr | -86.75 Cr | -279.09 Cr | -92.18 Cr |
| Adjustment | 49.68 Cr | 72.2 Cr | 203.3 Cr | 165.38 Cr |
| Changes In working Capital | -147.52 Cr | -147.82 Cr | -41.45 Cr | -114.62 Cr |
| Cash Flow after changes in Working Capital | -32.19 Cr | -162.37 Cr | -117.24 Cr | -41.42 Cr |
| Cash Flow from Operating Activities | -32.5 Cr | -158.31 Cr | -117.33 Cr | -41.57 Cr |
| Cash Flow from Investing Activities | -80.39 Cr | 104.03 Cr | 202.5 Cr | 53.24 Cr |
| Cash Flow from Financing Activitie | -45.19 Cr | 95.8 Cr | -61.76 Cr | -48.06 Cr |
| Net Cash Inflow / Outflow | -158.07 Cr | 41.53 Cr | 23.41 Cr | -36.39 Cr |
| Opening Cash & Cash Equivalents | 203.08 Cr | 52.6 Cr | 94.13 Cr | 155.67 Cr |
| Cash & Cash Equivalent on Amalgamation / Take over / Merger | 7.59 Cr | 0 | 38.13 Cr | 6.37 Cr |
| Closing Cash & Cash Equivalent | 52.6 Cr | 94.13 Cr | 155.67 Cr | 125.65 Cr |
CONSOLIDATED BALANCE SHEET FOR UNICHEM LABORATORIES LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 14.08 Cr | 14.08 Cr | 14.08 Cr | 14.08 Cr |
| Equity - Authorised | 35 Cr | 35 Cr | 35 Cr | 35 Cr |
| Equity - Issued | 14.08 Cr | 14.08 Cr | 14.08 Cr | 14.08 Cr |
| Equity Paid Up | 14.08 Cr | 14.08 Cr | 14.08 Cr | 14.08 Cr |
| Face Value | 2 | 2 | 2 | 2 |
| Total Reserves | 2535 Cr | 2593.65 Cr | 2409.18 Cr | 2345.27 Cr |
| Securities Premium | 1.33 Cr | 1.33 Cr | 1.33 Cr | 1.33 Cr |
| Profit & Loss Account Balance | 2501.18 Cr | 2506.08 Cr | 2397.51 Cr | 2339.08 Cr |
| Reserve excluding Revaluation Reserve | 2535 Cr | 2593.65 Cr | 2409.18 Cr | 2345.27 Cr |
| Shareholder's Funds | 2556.83 Cr | 2618.41 Cr | 2435.3 Cr | 2362.42 Cr |
| Secured Loans | 0 | 89.01 Cr | 63.65 Cr | 38.22 Cr |
| Term Loans - Banks | 0 | 89.01 Cr | 63.65 Cr | 38.22 Cr |
| Deferred Tax Assets / Liabilities | -25.14 Lk | -4.36 Cr | -10.11 Cr | -6.78 Cr |
| Deferred Tax Assets | 77.15 Cr | 93.94 Cr | 82.08 Cr | 95.74 Cr |
| Deferred Tax Liability | 76.89 Cr | 89.58 Cr | 71.97 Cr | 88.97 Cr |
| Other Long Term Liabilities | 19 Cr | 19.26 Cr | 12.59 Cr | 25.02 Cr |
| Long Term Provisions | 30.41 Cr | 39.96 Cr | 41.91 Cr | 35.8 Cr |
| Total Non-Current Liabilities | 49.16 Cr | 143.88 Cr | 108.03 Cr | 92.27 Cr |
| Trade Payables | 210.08 Cr | 183.19 Cr | 290.69 Cr | 299.37 Cr |
| Sundry Creditors | 210.08 Cr | 183.19 Cr | 290.69 Cr | 299.37 Cr |
| Other Current Liabilities | 176.97 Cr | 135.06 Cr | 128.34 Cr | 115.19 Cr |
| Advances received from customers | 28.29 Cr | 26.95 Cr | 24.53 Cr | 7.69 Cr |
| Short Term Borrowings | 100.62 Cr | 215.69 Cr | 208.08 Cr | 155.26 Cr |
| Secured ST Loans repayable on Demands | 100.62 Cr | 215.69 Cr | 208.08 Cr | 155.26 Cr |
| Working Capital Loans- Sec | 100.62 Cr | 215.69 Cr | 208.08 Cr | 155.26 Cr |
| Short Term Provisions | 18.09 Cr | 18.19 Cr | 12.5 Cr | 138.06 Cr |
| Provision for Tax | 3.26 Cr | 2.1 Cr | 49.14 Lk | 2.21 Cr |
| Provision for post retirement benefits | 3.72 Cr | 4.4 Cr | 0 | 0 |
| Total Current Liabilities | 505.76 Cr | 552.13 Cr | 639.6 Cr | 707.88 Cr |
| Total Liabilities | 3111.76 Cr | 3314.42 Cr | 3182.94 Cr | 3162.57 Cr |
| Gross Block | 1193.56 Cr | 1391.05 Cr | 1750.29 Cr | 1793.08 Cr |
| Less: Accumulated Depreciation | 313.14 Cr | 401.01 Cr | 493.63 Cr | 597.1 Cr |
| Net Block | 880.42 Cr | 990.03 Cr | 1256.66 Cr | 1195.97 Cr |
| Capital Work in Progress | 567.5 Cr | 493.81 Cr | 147.45 Cr | 122.72 Cr |
| Non Current Investments | 159.12 Cr | 28.47 Lk | 16.09 Lk | 2 Lk |
| Long Term Investment | 159.12 Cr | 28.47 Lk | 16.09 Lk | 2 Lk |
| Quoted | 15.03 Lk | 26.47 Lk | 14.09 Lk | 0 |
| Unquoted | 158.97 Cr | 4.89 Cr | 4.89 Cr | 4.89 Cr |
| Long Term Loans & Advances | 112.89 Cr | 165.59 Cr | 168.07 Cr | 124.91 Cr |
| Other Non Current Assets | 14.52 Cr | 16.3 Cr | 18.72 Cr | 21.45 Cr |
| Total Non-Current Assets | 1734.44 Cr | 1666.02 Cr | 1591.06 Cr | 1465.06 Cr |
| Currents Investments | 236.43 Cr | 263.58 Cr | 1.54 Cr | 1.34 Cr |
| Quoted | 236.43 Cr | 263.58 Cr | 1.25 Cr | 1.34 Cr |
| Unquoted | 158.97 Cr | 4.89 Cr | 4.89 Cr | 4.89 Cr |
| Inventories | 538.34 Cr | 600.22 Cr | 625.23 Cr | 704.68 Cr |
| Raw Materials | 213.06 Cr | 233.56 Cr | 253.57 Cr | 261.53 Cr |
| Work-in Progress | 77.46 Cr | 102.15 Cr | 81.38 Cr | 102.73 Cr |
| Finished Goods | 200.22 Cr | 221.75 Cr | 220.17 Cr | 282.15 Cr |
| Packing Materials | 23.72 Cr | 22.1 Cr | 25.13 Cr | 32.71 Cr |
| Stores and Spare | 8.97 Cr | 12.52 Cr | 13.87 Cr | 15.76 Cr |
| Sundry Debtors | 250.27 Cr | 495.43 Cr | 588.62 Cr | 610.4 Cr |
| Debtors more than Six months | 0 | 2.27 Cr | 3.09 Cr | 45.11 Cr |
| Debtors Others | 255.19 Cr | 496.36 Cr | 588.49 Cr | 568.72 Cr |
| Cash and Bank | 82.45 Cr | 114.1 Cr | 185.36 Cr | 154.32 Cr |
| Cash in hand | 7.27 Lk | 8.3 Lk | 5.1 Lk | 4.5 Lk |
| Balances at Bank | 82.38 Cr | 114.02 Cr | 185.31 Cr | 154.28 Cr |
| Other Current Assets | 62.21 Cr | 38.07 Cr | 33.76 Cr | 29.33 Cr |
| Interest accrued on Debentures | 8.82 Cr | 55.07 Lk | 12.42 Lk | 23.09 Lk |
| Prepaid Expenses | 19 Cr | 21.05 Cr | 23.43 Cr | 20.66 Cr |
| Short Term Loans and Advances | 207.62 Cr | 136.99 Cr | 153.96 Cr | 194.1 Cr |
| Advances recoverable in cash or in kind | 16.95 Cr | 9.38 Cr | 5.03 Cr | 14.55 Cr |
| Total Current Assets | 1377.32 Cr | 1648.39 Cr | 1588.47 Cr | 1694.16 Cr |
| Net Current Assets (Including Current Investments) | 871.56 Cr | 1096.27 Cr | 948.86 Cr | 986.28 Cr |
| Total Assets | 3111.76 Cr | 3314.42 Cr | 3182.94 Cr | 3162.57 Cr |
| Contingent Liabilities | 151.65 Cr | 145.39 Cr | 151.04 Cr | 32.35 Cr |
| Total Debt | 100.62 Cr | 330.36 Cr | 297.39 Cr | 219.15 Cr |
| Book Value | 362.06 | 0 | 344.18 | 335.11 |
| Adjusted Book Value | 362.06 | 370.39 | 344.18 | 335.11 |
STANDALONE BALANCE SHEET FOR UNICHEM LABORATORIES LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Share Capital | 14.08 Cr | 14.08 Cr | 14.08 Cr | 14.08 Cr |
| Equity - Authorised | 35 Cr | 35 Cr | 35 Cr | 35 Cr |
| Equity - Issued | 14.08 Cr | 14.08 Cr | 14.08 Cr | 14.08 Cr |
| Equity Paid Up | 14.08 Cr | 14.08 Cr | 14.08 Cr | 14.08 Cr |
| Face Value | 2 | 2 | 2 | 2 |
| Total Reserves | 2675.5 Cr | 2647.28 Cr | 2358.14 Cr | 2277.48 Cr |
| Securities Premium | 1.33 Cr | 1.33 Cr | 1.33 Cr | 1.33 Cr |
| Profit & Loss Account Balance | 2648.96 Cr | 2565.36 Cr | 2359.31 Cr | 2279.18 Cr |
| Reserve excluding Revaluation Reserve | 2675.5 Cr | 2647.28 Cr | 2358.14 Cr | 2277.48 Cr |
| Shareholder's Funds | 2697.33 Cr | 2672.04 Cr | 2384.27 Cr | 2294.63 Cr |
| Secured Loans | 0 | 89.01 Cr | 63.65 Cr | 38.22 Cr |
| Term Loans - Banks | 0 | 89.01 Cr | 63.65 Cr | 38.22 Cr |
| Deferred Tax Assets / Liabilities | 13.7 Cr | 0 | 0 | 0 |
| Deferred Tax Assets | 62.63 Cr | 88.99 Cr | 71.45 Cr | 88.3 Cr |
| Deferred Tax Liability | 76.34 Cr | 88.99 Cr | 71.45 Cr | 88.3 Cr |
| Other Long Term Liabilities | 6.15 Cr | 10.65 Cr | 7.65 Cr | 7.11 Cr |
| Long Term Provisions | 30.41 Cr | 39.96 Cr | 41.91 Cr | 35.8 Cr |
| Total Non-Current Liabilities | 50.27 Cr | 139.63 Cr | 113.21 Cr | 81.13 Cr |
| Trade Payables | 188.57 Cr | 157.08 Cr | 244.47 Cr | 249.49 Cr |
| Sundry Creditors | 188.57 Cr | 157.08 Cr | 244.47 Cr | 249.49 Cr |
| Other Current Liabilities | 168.06 Cr | 125.82 Cr | 119.82 Cr | 102.6 Cr |
| Advances received from customers | 28.29 Cr | 26.95 Cr | 24.53 Cr | 7.69 Cr |
| Short Term Borrowings | 0 | 11.43 Cr | 12.36 Cr | 0 |
| Secured ST Loans repayable on Demands | 0 | 11.43 Cr | 12.36 Cr | 0 |
| Working Capital Loans- Sec | 0 | 11.43 Cr | 12.36 Cr | 0 |
| Short Term Provisions | 14.83 Cr | 16.09 Cr | 12.01 Cr | 135.85 Cr |
| Provision for post retirement benefits | 3.72 Cr | 4.4 Cr | 0 | 0 |
| Total Current Liabilities | 371.45 Cr | 310.42 Cr | 388.66 Cr | 487.94 Cr |
| Total Liabilities | 3119.06 Cr | 3122.08 Cr | 2886.14 Cr | 2863.7 Cr |
| Gross Block | 1129.16 Cr | 1325.15 Cr | 1690.9 Cr | 1718.31 Cr |
| Less: Accumulated Depreciation | 282.93 Cr | 362.03 Cr | 454.95 Cr | 553.37 Cr |
| Net Block | 846.23 Cr | 963.12 Cr | 1235.94 Cr | 1164.94 Cr |
| Capital Work in Progress | 567.73 Cr | 494.18 Cr | 147.82 Cr | 122.36 Cr |
| Non Current Investments | 287.52 Cr | 126.22 Cr | 38.98 Cr | 42.73 Cr |
| Long Term Investment | 287.52 Cr | 126.22 Cr | 38.98 Cr | 42.73 Cr |
| Quoted | 15.03 Lk | 26.47 Lk | 14.09 Lk | 0 |
| Unquoted | 358.24 Cr | 202.51 Cr | 205.54 Cr | 209.44 Cr |
| Long Term Loans & Advances | 112.21 Cr | 164.61 Cr | 167.22 Cr | 124.18 Cr |
| Total Non-Current Assets | 1813.69 Cr | 1748.12 Cr | 1589.96 Cr | 1454.22 Cr |
| Currents Investments | 236.43 Cr | 263.58 Cr | 1.54 Cr | 1.34 Cr |
| Quoted | 236.43 Cr | 263.58 Cr | 1.25 Cr | 1.34 Cr |
| Unquoted | 358.24 Cr | 202.51 Cr | 205.54 Cr | 209.44 Cr |
| Inventories | 386.12 Cr | 460.69 Cr | 480.19 Cr | 500.53 Cr |
| Raw Materials | 207.77 Cr | 229.77 Cr | 249.08 Cr | 250.66 Cr |
| Work-in Progress | 77.46 Cr | 102.15 Cr | 81.38 Cr | 102.73 Cr |
| Finished Goods | 53.56 Cr | 86.01 Cr | 83.15 Cr | 89.2 Cr |
| Packing Materials | 23.72 Cr | 22.1 Cr | 25.13 Cr | 32.71 Cr |
| Stores and Spare | 8.97 Cr | 12.52 Cr | 13.87 Cr | 15.76 Cr |
| Sundry Debtors | 360.48 Cr | 380.84 Cr | 472.08 Cr | 558.42 Cr |
| Debtors more than Six months | 0 | 30.37 Cr | 29.2 Cr | 11.55 Cr |
| Debtors Others | 365.41 Cr | 353.68 Cr | 445.83 Cr | 550.29 Cr |
| Cash and Bank | 57.59 Cr | 99.03 Cr | 157.28 Cr | 129.06 Cr |
| Cash in hand | 7.21 Lk | 8.11 Lk | 5.01 Lk | 4.38 Lk |
| Balances at Bank | 57.51 Cr | 98.95 Cr | 157.23 Cr | 129.02 Cr |
| Other Current Assets | 57.62 Cr | 33.46 Cr | 28.38 Cr | 23.93 Cr |
| Interest accrued on Debentures | 8.82 Cr | 55.07 Lk | 12.42 Lk | 23.09 Lk |
| Prepaid Expenses | 14.41 Cr | 16.44 Cr | 18.05 Cr | 15.26 Cr |
| Short Term Loans and Advances | 207.13 Cr | 136.35 Cr | 153.31 Cr | 192.86 Cr |
| Advances recoverable in cash or in kind | 16.46 Cr | 8.74 Cr | 4.38 Cr | 13.6 Cr |
| Total Current Assets | 1305.37 Cr | 1373.96 Cr | 1292.76 Cr | 1406.13 Cr |
| Net Current Assets (Including Current Investments) | 933.91 Cr | 1063.54 Cr | 904.1 Cr | 918.2 Cr |
| Total Assets | 3119.06 Cr | 3122.08 Cr | 2886.14 Cr | 2863.7 Cr |
| Contingent Liabilities | 177.17 Cr | 170.79 Cr | 177.54 Cr | 58.93 Cr |
| Total Debt | 0 | 126.1 Cr | 101.68 Cr | 63.89 Cr |
| Book Value | 382.01 | 378 | 336.94 | 325.48 |
| Adjusted Book Value | 382.01 | 378 | 336.94 | 325.48 |
FINANCIAL RATIOS (CONSOLIDATED) FOR UNICHEM LABORATORIES LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 4.88 | 4.7 | -28.72 | -10.01 |
| CEPS(Rs) | 16.91 | 17.8 | -12.61 | 6.07 |
| DPS(Rs) | 4 | 4 | 0 | 0 |
| Book NAV/Share(Rs) | 362.06 | 370.39 | 344.18 | 335.11 |
| Tax Rate(%) | 33.1 | -48.17 | -14.67 | -14.28 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 7.38 | 5.73 | -3.39 | 5.88 |
| EBIT Margin(%) | 4.61 | 2.29 | -11.84 | -2.29 |
| Pre Tax Margin(%) | 4.2 | 1.81 | -13.13 | -3.62 |
| PAT Margin (%) | 2.81 | 2.69 | -15.06 | -4.13 |
| Cash Profit Margin (%) | 9.64 | 9.87 | -6.61 | 2.51 |
| Performance Ratios | ||||
| ROA(%) | 1.11 | 1.06 | -6.22 | -2.22 |
| ROE(%) | 1.37 | 1.32 | -8.04 | -2.95 |
| ROCE(%) | 2.12 | 1.04 | -5.6 | -1.47 |
| Asset Turnover(x) | 0.4 | 0.4 | 0.41 | 0.54 |
| Sales/Fixed Asset(x) | 1.08 | 0.98 | 0.86 | 0.96 |
| Working Capital/Sales(x) | 1.42 | 1.16 | 1.42 | 1.73 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.93 | 1.02 | 1.17 | 1.04 |
| Receivable days | 94.63 | 107.17 | 147.31 | 128.35 |
| Inventory Days | 138.14 | 163.63 | 166.52 | 142.36 |
| Payable days | 70.25 | 201.09 | 179.26 | 190.38 |
| Valuation Parameters | ||||
| PER(x) | 63.44 | 55.44 | 0 | 0 |
| PCE(x) | 18.3 | 14.63 | -22.92 | 80.42 |
| Price/Book(x) | 0.85 | 0.7 | 0.84 | 1.46 |
| Yield(%) | 1.29 | 1.54 | 0 | 0 |
| EV/Net Sales(x) | 1.78 | 1.61 | 1.6 | 2.06 |
| EV/Core EBITDA(x) | 15.54 | 17.03 | -304.98 | 26.58 |
| EV/EBIT(x) | 38.56 | 70.34 | -13.5 | -89.84 |
| EV/CE(x) | 0.71 | 0.62 | 0.67 | 1.36 |
| M Cap / Sales | 1.76 | 1.44 | 1.52 | 2.02 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 11.91 | 2.81 | 5.76 | 26.94 |
| Core EBITDA Growth(%) | 248.94 | -14.86 | -105.85 | 1972.69 |
| EBIT Growth(%) | 238.29 | -48.83 | -666.54 | 75.48 |
| PAT Growth(%) | 156.84 | -1.57 | -711.67 | 65.15 |
| EPS Growth(%) | 157.04 | -3.68 | -711.66 | 65.15 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0.04 | 0.13 | 0.12 | 0.09 |
| Current Ratio(x) | 2.72 | 2.99 | 2.48 | 2.39 |
| Quick Ratio(x) | 1.66 | 1.9 | 1.51 | 1.4 |
| Interest Cover(x) | 11.12 | 4.77 | -9.19 | -1.72 |
| Total Debt/Mcap(x) | 0.05 | 0.18 | 0.15 | 0.06 |
FINANCIAL RATIOS (STANDALONE) FOR UNICHEM LABORATORIES LIMITED
| YEAR | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 |
|---|---|---|---|---|
| Operational & Financial Ratios | ||||
| Earnings Per Share (Rs) | 7.68 | -7.87 | -42.57 | -13.09 |
| CEPS(Rs) | 18.46 | 3.94 | -27.52 | 1.89 |
| DPS(Rs) | 4 | 4 | 0 | 0 |
| Book NAV/Share(Rs) | 382.01 | 378 | 336.94 | 325.48 |
| Tax Rate(%) | 17.61 | 36.1 | -7.39 | 0 |
| Margin Ratios | ||||
| Core EBITDA Margin(%) | 8.49 | -4.62 | -8.66 | 3.53 |
| EBIT Margin(%) | 5.96 | -8.98 | -25.15 | -5.67 |
| Pre Tax Margin(%) | 5.84 | -9.2 | -26.02 | -6.39 |
| PAT Margin (%) | 4.81 | -5.88 | -27.95 | -6.39 |
| Cash Profit Margin (%) | 11.56 | 2.94 | -18.06 | 0.92 |
| Performance Ratios | ||||
| ROA(%) | 1.76 | -1.78 | -9.98 | -3.21 |
| ROE(%) | 2.03 | -2.07 | -11.91 | -3.95 |
| ROCE(%) | 2.5 | -3.08 | -10.21 | -3.38 |
| Asset Turnover(x) | 0.37 | 0.3 | 0.36 | 0.5 |
| Sales/Fixed Asset(x) | 1.04 | 0.77 | 0.71 | 0.85 |
| Working Capital/Sales(x) | 1.2 | 0.89 | 1.19 | 1.57 |
| Efficiency Ratios | ||||
| Fixed Capital/Sales(x) | 0.96 | 1.3 | 1.41 | 1.18 |
| Receivable days | 110.99 | 143.48 | 145.15 | 130.4 |
| Inventory Days | 113.93 | 163.9 | 160.11 | 124.11 |
| Payable days | 75.71 | 194.36 | 160.92 | 152.16 |
| Valuation Parameters | ||||
| PER(x) | 40.27 | 0 | 0 | 0 |
| PCE(x) | 16.75 | 66.04 | -10.51 | 259.03 |
| Price/Book(x) | 0.81 | 0.69 | 0.86 | 1.5 |
| Yield(%) | 1.29 | 1.54 | 0 | 0 |
| EV/Net Sales(x) | 1.89 | 1.97 | 1.85 | 2.34 |
| EV/Core EBITDA(x) | 14.84 | -1251.83 | -38.76 | 41.5 |
| EV/EBIT(x) | 31.67 | -21.97 | -7.34 | -41.27 |
| EV/CE(x) | 0.68 | 0.6 | 0.69 | 1.43 |
| M Cap / Sales | 1.94 | 1.94 | 1.9 | 2.38 |
| Growth Ratio | ||||
| Net Sales Growth(%) | 24.27 | -16.11 | 13.73 | 34.48 |
| Core EBITDA Growth(%) | 1568.74 | -101.04 | -3336.7 | 259.22 |
| EBIT Growth(%) | 207.06 | -226.48 | -218.53 | 69.69 |
| PAT Growth(%) | 196.03 | -202.49 | -440.69 | 69.24 |
| EPS Growth(%) | 196.03 | -202.49 | -440.69 | 69.24 |
| Financial Stability Ratios | ||||
| Total Debt/Equity(x) | 0 | 0.05 | 0.04 | 0.03 |
| Current Ratio(x) | 3.51 | 4.43 | 3.33 | 2.88 |
| Quick Ratio(x) | 2.47 | 2.94 | 2.09 | 1.86 |
| Interest Cover(x) | 51.47 | -40.82 | -28.75 | -7.85 |
| Total Debt/Mcap(x) | 0 | 0.07 | 0.05 | 0.02 |
SHARE HOLDING PATTERN FOR UNICHEM LABORATORIES LIMITED
| Date | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoters % | 50.93 | 50.93 | 50.93 | 50.93 | 50.93 | 70.21 | 70.22 | 70.22 | 70.22 | 70.22 |
| FII % | 1.50 | 1.71 | 1.56 | 1.70 | 1.62 | 0.83 | 0.84 | 0.90 | 0.89 | 0.94 |
| DII % | 1.15 | 1.15 | 1.16 | 1.20 | 2.25 | 1.18 | 1.17 | 1.23 | 1.18 | 1.18 |
| Public % | 38.04 | 38.66 | 39.30 | 39.21 | 37.80 | 18.95 | 18.47 | 17.61 | 17.30 | 17.18 |
PEER COMPARISON FOR UNICHEM LABORATORIES LIMITED
CORPORATE ACTIONS FOR UNICHEM LABORATORIES
| Exchange Date | Purpose | Book Closure Dates |
|---|---|---|
| BSE 25-Oct-2024 | Board Meeting - Quarterly Results | 13-Nov-2024 |
| BSE 23-Sep-2024 | Board Meeting - Inter alia, to consider and approve:- (1) integration and consolidation of the generics formulations business in the US market. | 30-Sep-2024 |
| BSE 26-Jul-2024 | Board Meeting - Quarterly Results | 08-Aug-2024 |
| BSE 09-May-2024 | Board Meeting - Audited Results | 22-May-2024 |
| BSE 15-Jan-2024 | Board Meeting - Quarterly Results | 05-Feb-2024 |
| BSE 18-Oct-2023 | Board Meeting - Quarterly Results | 01-Nov-2023 |
| BSE 05-Jul-2023 | Board Meeting - Quarterly Results | 14-Jul-2023 |
| BSE 15-May-2023 | Board Meeting - Audited Results | 23-May-2023 |
| BSE 24-Apr-2023 | SAST - Inter alia, approved:- Dr. Prakash Amrut Mody, one of the members of the promoter and promoter group of the Company (?Seller?), and IPCA Laboratories Limited (?Acquirer?) have entered into a share purchase agreement dated 24 April 2023 (?SPA?) whereby the Acquirer has agreed to purchase 2,35,01,440 fully paid-up equity shares of Rs. 2/- each, constituting 33.38 % of the fully diluted voting share ... | 24-Apr-2023 |
| BSE 27-Jan-2023 | Board Meeting - Quarterly Results | 06-Feb-2023 |
| BSE 03-Nov-2022 | Board Meeting - Quarterly Results | 11-Nov-2022 |
| BSE 01-Aug-2022 | Board Meeting - Quarterly Results | 09-Aug-2022 |
| BSE 28-Jun-2022 | Book Closure - 20/08/2022 Equity Rs.4.0000 per share(200%)Final Dividend & A.G.M. | 03-Aug-2022 09-Aug-2022 |
| BSE 28-Jun-2022 | AGM - 20/08/2022 Equity Rs.4.0000 per share(200%)Final Dividend & A.G.M. | 09-Aug-2022 09-Aug-2022 |
| BSE 27-May-2022 | Dividend - Rs.4.0000 per share(200%)Final Dividend | |
| BSE 19-May-2022 | Board Meeting - Final Dividend & Audited Results | 27-May-2022 |
| BSE 21-Jan-2022 | Board Meeting - Quarterly Results | 29-Jan-2022 |
| BSE 25-Oct-2021 | Board Meeting - Quarterly Results | 02-Nov-2021 |
CORPORATE ANNOUNCEMENTS FOR UNICHEM LABORATORIES
| Exchange Date | Category File | Description |
|---|---|---|
| BSE 25-Oct-2024 | Intimation FILE | Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended September 30 2024. UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Unaudited Financial Results for the quarter ended September 30 2024. |
| BSE 23-Oct-2024 | General Announcements FILE | Reply Letter On A Significant Increase In The Volume. Reply letter on a significant increase in the Volume. |
| BSE 11-Oct-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended September 30 2024. |
| BSE 04-Oct-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Compliance Reg. 39 (3) - Intimation of Loss of Share certificate |
| BSE 30-Sep-2024 | Outcome FILE | Board Meeting Outcome for Outcome Of Board Meeting Purchase of Product approvals and all goodwill associated with Nine (9) ANDAs owned by Bayshore Pharmaceuticals LLC USA for USD 2 650 000 by the Company and Purchase of USA generics formulations business as a going concern through slump sale ./ transfer of business by Unichem Pharmaceuticals (USA) Inc through assets purchase agreements for USD 10 000 000. |
| BSE 23-Sep-2024 | Intimation FILE | Closure of Trading Window Trading window shall be closed from 23.09.2024 to till 48 Hrs after declaration of financial results and other matters. |
| BSE 23-Sep-2024 | Intimation FILE | Board Meeting Intimation for Integration And Consolidation Of The Generics FormulationsBusiness In The US Market. UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/09/2024 inter alia to consider and approve integration and consolidation of the generics formulations business in the US market. |
| BSE 10-Sep-2024 | General Announcements FILE | Intimation Under Regulation 30 Of SEBI LODR Intimation under Regulation 30 of SEBI LODR |
| BSE 03-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Publication - Change of Registered office |
| BSE 03-Sep-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Change in Registered Office Address Intimation regarding a change in the Registered Office of Unichem Laboratories Ltd. |
| BSE 23-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Compliance - Issue of duplicate share certificate. |
| BSE 09-Aug-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Financial Results for the quarter ended June 30 2024 published in the newspapers on August 9 2024. |
| BSE 08-Aug-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Scrutinizer''s Report Voting Results & Scrutinizers report for AGM |
| BSE 08-Aug-2024 | Outcome FILE | Shareholder Meeting / Postal Ballot-Outcome of AGM AGM Proceedings |
| BSE 08-Aug-2024 | General Announcements FILE | Change In Key Managerial Personnel For Determining And Disclosure Of Material Events KMP for determining & disclosing material events |
| BSE 08-Aug-2024 | Outcome FILE | Board Meeting Outcome for Outcome Of Board Meeting Outcome of Board Meeting |
| BSE 08-Aug-2024 | Outcome FILE | Outcome Of Board Meeting PFA herewith Outcome of Board Meeting |
| BSE 05-Aug-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of loss of share Certificate |
| BSE 26-Jul-2024 | Intimation FILE | Board Meeting Intimation for Financial Results UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve Unaudited financial results (standalone & consolidated) for the quarter ended 30th June 2024. |
| BSE 15-Jul-2024 | General Announcements FILE | USFDA Inspection At Goa Formulation Facility Pl. find enclosed disclosure under regulation 30 of LODR |
| BSE 12-Jul-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Newspaper Publication regarding e-voting information for 61st Annual General Meeting of the Company. |
| BSE 11-Jul-2024 | General Announcements FILE | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulation 2018 for Quarter ended June 30 2024 |
| BSE 11-Jul-2024 | General Announcements FILE | Notice Of The 61St Annual General Meeting Notice of the 61st Annual General Meeting to be held on August 8 2024 |
| BSE 11-Jul-2024 | General Announcements FILE | Business Responsibility and Sustainability Reporting (BRSR) Business Responsibility and Sustainability Report 2023-24 |
| BSE 11-Jul-2024 | General Announcements FILE | Reg. 34 (1) Annual Report. Annual Report for the year 2023-24 |
| BSE 01-Jul-2024 | General Announcements FILE | Announcement under Regulation 30 (LODR)-Newspaper Publication Announcement under Regulation 30 (LODR)- Newspaper Publication. |
| BSE 01-Jul-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Intimation of Loss of Share Certificate |
| BSE 28-Jun-2024 | Intimation FILE | Shareholder Meeting - AGM On August 8 2024 Shareholder Meeting - AGM on August 8 2024 |
| BSE 27-Jun-2024 | General Announcements FILE | Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 Pl. find attached herewith intimation u/r. 30 of LODR. |
| BSE 26-Jun-2024 | General Announcements FILE | Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate Compliances-Reg 39(3) - Details of Loss of Share certificate. |
INSIDER TRADING FOR UNICHEM LABORATORIES
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| BSE 21-Sep-2023 21-Sep-2023 | Sell Others | 4,646 @ 0.00 (0.00 %) | GERARD MAJELLA COLE |
| BSE 21-Sep-2023 21-Sep-2023 | Sell Others | 4,000 @ 0.00 (0.00 %) | RAJARAM PAI |
| BSE 21-Sep-2023 21-Sep-2023 | Sell Others | 13,200 @ 0.00 (0.00 %) | JATIN RAMANLAL MEHTA |
| BSE 22-Aug-2023 22-Aug-2023 | Sell Market | 6,000 @ 0.00 (0.00 %) | VANDANA PANDEY |
| BSE 21-Aug-2023 22-Aug-2023 | Sell Market | 5,000 @ 0.00 (0.00 %) | DILIP KUNKOLIENKAR |
| BSE 17-Aug-2023 18-Aug-2023 | Sell Market | 5,000 @ 0.00 (0.00 %) | DILIP KUNKOLIENKAR |
| BSE 14-Aug-2023 14-Aug-2023 | Sell Market | 30,000 @ 0.00 (0.05 %) | DILIP KUNKOLIENKAR |
| BSE 02-Aug-2023 14-Aug-2023 | Sell Market | 3,339 @ 0.00 (0.00 %) | JALESH BURYE |
| BSE 02-Aug-2023 04-Aug-2023 | Sell Market | 16,259 @ 0.00 (0.02 %) | DILIP KUNKOLIENKAR |
| BSE 31-Jul-2023 01-Aug-2023 | Sell Market | 19,000 @ 0.00 (0.02 %) | DILIP KUNKOLIENKAR |
| BSE 02-Aug-2023 02-Aug-2023 | Sell Others | 23,501,400 @ 0.00 (33.38 %) | DR PRAKASH A MODY |
| BSE 25-Jul-2023 25-Jul-2023 | Sell Market | 3,029 @ 0.00 (0.00 %) | ANAND MAHAJAN |
| BSE 25-Jul-2023 25-Jul-2023 | Sell Market | 2,836 @ 0.00 (0.00 %) | VERA MAHAJAN |
| BSE 21-Jul-2023 21-Jul-2023 | Sell Market | 2,000 @ 0.00 (0.00 %) | VERA MAHAJAN |
| BSE 24-Jul-2023 24-Jul-2023 | Sell Market | 2,000 @ 0.00 (0.00 %) | VERA MAHAJAN |
| BSE 24-Jul-2023 24-Jul-2023 | Sell Market | 1,000 @ 0.00 (0.00 %) | ANAND MAHAJAN |
| BSE 21-Jul-2023 21-Jul-2023 | Sell Market | 1,000 @ 0.00 (0.00 %) | ANAND MAHAJAN |
| BSE 05-Jun-2023 05-Jun-2023 | Sell Market | 2,750 @ 0.00 (0.00 %) | VERA MAHAJAN |
| BSE 05-Jun-2023 05-Jun-2023 | Sell Market | 6,312 @ 0.00 (0.00 %) | AAKIL A MAHAJAN |
| BSE 05-Jun-2023 05-Jun-2023 | Sell Market | 1,750 @ 0.00 (0.00 %) | ANAND MAHAJAN |
| BSE 01-Jun-2023 01-Jun-2023 | Sell Market | 1,800 @ 0.00 (0.00 %) | ANAND MAHAJAN |
| BSE 01-Jun-2023 01-Jun-2023 | Sell Market | 2,800 @ 0.00 (0.01 %) | VERA MAHAJAN |
| BSE 31-May-2023 02-Jun-2023 | Sell Market | 4,450 @ 0.00 (0.01 %) | ANAND MAHAJAN |
| BSE 31-May-2023 02-Jun-2023 | Sell Market | 6,950 @ 0.00 (0.01 %) | VERA MAHAJAN |
| BSE 31-May-2023 31-May-2023 | Sell Market | 7,450 @ 0.00 (0.00 %) | VIDHYA ANANTHARAMAN |
| BSE 29-May-2023 29-May-2023 | Sell Market | 682 @ 0.00 (0.00 %) | PRAFUL ANUBHAI |
| BSE 29-May-2023 29-May-2023 | Sell Market | 26,496 @ 0.00 (0.00 %) | RUPANDE PRAFULLBHAI SHAH |
| BSE 31-Jan-2023 31-Jan-2023 | Sell Inheritance | 49,908 @ 0.00 (0.00 %) | ASHOK SHAH |
| BSE 20-Jan-2023 20-Jan-2023 | Buy Inheritance | 49,908 @ 0.00 (0.00 %) | ASHOK SHAH |
BULK BLOCK DEALS FOR UNICHEM LABORATORIES LIMITED
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| No Bulk Block details found | |||
DIVIDEND BY UNICHEM LABORATORIES LIMITED
| Ex Dividend Date | Dividend Type | Dividend |
|---|---|---|
| 01-Aug-2022 | DIVIDEND | 4 |
| 22-Jul-2021 | DIVIDEND | 4 |
SPLIT / BONUS BY UNICHEM LABORATORIES LIMITED
No Split / Bonus details found
Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed
